FDA launches Real-World Evidence Program

The U.S. FDA recently issued several guidances relating to Real-World Evidence /-Data (e.g. How to Submit Documents with Real-World Data to FDA, Real-World Data). Now the agency is conducting an Advancing Real-World Evidence (RWE) Program, which seeks to improve the quality and acceptability of RWE-based approaches in support of new intended labeling claims. For selected product sponsors, the Program provides the opportunity to meet with FDA staff in CDER /  CBER - before protocol development or study initiation - to discuss the use of RWE in medical product development. However, "the Advancing RWE Program is an optional pathway for sponsors submitting RWE proposals; established procedures to engage the agency will continue to be available".

Goals of the RWE Program

The Advancing RWE Program is designed to:

  • Identify approaches for generating RWE for effectiveness labeling (e.g., new indications, populations, dosing information) or for meeting post-approval study requirements,
  • Develop agency processes that promote consistent decision-making and shared learning regarding RWE,
  • Promote awareness that RWE can support regulatory decisions.

Sponsors may submit an initial meeting request to the Advancing RWE program on a rolling basis through March 31, 2027. FDA will review all meeting requests received in the preceding 6-month submission cycle after each submission deadline.

More information on the program is available on FDA´s Advancing Real-World Evidence Program webpage.

Go back


Stay informed with the GMP Newsletters from ECA

GMP Newsletter

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, please click here.